Specialized Histopathology

$506,028P30FY2015CANIH

Dana-Farber Cancer Inst, Boston MA

Investigators

Linked publications, trials & patents

Paper 39713466 Paper 39666914 Paper 39605676 Paper 39593217 Paper 39536083 Paper 39532885 Paper 39484503 Paper 39389170 Paper 39322760 Paper 39168126 Paper 39160372 Paper 39107288 Paper 39042477 Paper 39025073 Paper 39024561 Paper 38996877 Paper 38992034 Paper 38979326 Paper 38979245 Paper 38942046 Paper 38924531 Paper 38889153 Paper 38861327 Paper 38815709 Trial NCT03029325 Trial NCT02627430 Trial NCT02142803 Trial NCT02097225 Trial NCT02079740 Trial NCT01940809 Trial NCT01835184 Trial NCT01822509 Trial NCT01575522 Trial NCT01434316 Trial NCT01307631 Trial NCT01283035 Trial NCT01116648 Trial NCT01026324 Trial NCT00956163 Trial NCT00888134 Trial NCT00662506 Trial NCT00622401 Trial NCT00458978 Trial NCT00458549 Trial NCT00429910 Trial NCT00400946 Trial NCT00376480 Trial NCT00357500 Trial NCT00301093 Trial NCT00126672 Trial NCT00101075 Trial NCT00098865 Trial NCT00098514 Trial NCT00096291 Trial NCT00095927 Trial NCT00095901 Trial NCT00095875 Trial NCT00095836 Trial NCT00090857 Trial NCT00084838 Trial NCT00083031 Trial NCT00079326 Trial NCT00072436 Trial NCT00069940 Trial NCT00053976 Trial NCT00052611 Trial NCT00047294 Trial NCT00047281 Trial NCT00020670 Trial NCT00020605 Trial NCT00007917 Trial NCT00006107 Trial NCT00005988 Trial NCT00005096 Trial NCT00004180 Trial NCT00004163 Trial NCT00004070 Trial NCT00003761 Trial NCT00003744 Trial NCT00003657 Trial NCT00003200 Trial NCT00003058 Trial NCT00003045 Patent 9512485 Patent 7786269 Patent 7396678 Patent 7229755 Patent 7048929 Patent 6908617 Patent 6479284 Patent 6479281 Patent 5861424 Patent 5670530 Patent 5618831 Patent 5502214 Patent 5360803 Patent 4625014 Patent 4618492 Patent 4542225 Patent 4035566

Abstract

PROJECT SUMMARY (See instructions): The Specialized Histopathology Core was first approved and funded through the CCSG mechanism in 2005. The Core delivers services in a timely fashion and provides the geographically dispersed Cancer Center members with appropriate access to pathology consultative and interpretive services. There are two performance sites: Longwood (which is within minutes of six of the member institutions) and MGH, based at Massachusetts General Hospital. These two locations have enabled the Core to continue to grow and improve service delivery by increasing overall capacity, space and affiliated professional expertise. A full understanding of cancer pathogenesis and response to therapies requires access to technologies and professional expertise that allow cancer cells and biomarkers to be analyzed in situ. The Specialized Histopathology Services (SHP) Core meets this need by providing technical and professional pathology services to Dana-Farber/Harvard Cancer Center (DF/HCC) investigators conducting research with experimental organisms (e.g., rodents, fish, and monkeys) or human tissues. This facility also assists with experimental design and data interpretation. Director(s): Jon Aster, MD, PhD(BMW), Anat Stemmer-Rachamimov, MD(MGH) Category: 4.06 (Human Tissue Acquisition & Pathology/Histology) Management: Joint (Cancer Center and Institutional)

View original record on NIH RePORTER →